CEO: Ms. Angela Giannoccaro

IPO: 1998-10-16

Headquarters: US

Employees: 0

Homepage

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

Sierra Oncology Inc

Citius Pharmaceuticals Inc

Checkmate Pharmaceuticals Inc

Immuron Ltd

Immuron Ltd